Cisplatin and rt
WebRadiotherapy (RT) was given concurrently with cisplatin and etoposide. G-CSF was given as primary or secondary prophylaxis or as a therapeutic measure during an episode of febrile neutropenia according to local protocols. Common terminology criteria for adverse events (CTCAE) v3.0 was used to record toxicity. WebResults: RT was delivered according to the treatment plan in 104 patients and full dose was given to 107 patients. A median cumulative cisplatin dose of 240 mg/m2was …
Cisplatin and rt
Did you know?
WebThe oral vinorelbine-cisplatin combination with concurrent RT is feasible and has a favorable risk-benefit ratio in stage IIIA/IIIB NSCLC. Oral vinorelbine and cisplatin with … WebTherapeutic efficacy of cisplatin-based treatment of late stage urothelial carcinoma (UC) is limited by chemoresistance. To elucidate underlying mechanisms and to develop new approaches for overcoming resistance, we generated long-term cisplatin treated (LTT) UC cell lines, characterised their cisplatin response, and determined the expression of …
WebCisplatin is a chemotherapy drug. You might have it as a treatment for a number of different types of cancer. You might have cisplatin on its own or in combination with other … WebThe oral vinorelbine-cisplatin combination with concurrent RT is feasible and has a favorable risk-benefit ratio in stage IIIA/IIIB NSCLC. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study
WebCurrent standard for locally advanced non-small cell lung cancer (NSCLC) is combined concurrent therapy with a platinum-based regimen. Preclinical synergistic activity of pemetrexed with radiation therapy (RT) and favorable toxicity profile has led to clinical trials evaluating pemetrexed in chemoradiation regimens. WebJun 4, 2024 · Weekly cisplatin plus radiotherapy (RT) should be considered standard care in patients with locally advanced head and neck squamous cell carcinoma (HNSCC), …
WebSep 10, 2024 · Outcome: Median time-to-progression RT 6 months vs. RT + cisplatin 45 months vs. RT + carboplatin 18 months (SS); median OS 1 year vs. 4 years vs. 2 years (SS); 3-year OS 17% vs. 52% vs. 42% (SS) Toxicity: more severe N/V in RT + cisplatin
WebMar 15, 2024 · - Carboplatin and paclitaxel with RT for EGJ cancer - Cisplatin FU RT for EGJ cancer - Pembrolizumab monotherapy - Nivolumab for resected esophageal or gastroesophageal cancer; RELATED TOPICS. Adjuvant and neoadjuvant treatment of gastric cancer; Initial systemic therapy for locally advanced unresectable and metastatic … sap forecasting tableWeb2 days ago · One of the main problems in chemotherapy using platinum drugs as anticancer agents is the resistance phenomenon. Synthesizing and evaluating valid alternative compounds is challenging. This review focuses on the last two years of progress in the studies of platinum (II)- and platinum (IV)-based anticancer complexes. In particular, the … short suppressorWebIn the irinotecan-plus-cisplatin group, a 63-year-old man died of bleeding from a metastatic site in the lung, a 62-year-old man died of sepsis associated with neutropenia and diarrhea, and a... sap forecasting softwareWebApr 14, 2024 · Among the extracellular vesicles, apoptotic bodies (ABs) are only formed during the apoptosis and perform a relevant role in the pathogenesis of different … sap forecasting toolWebThe TPF triplet regimen (docetaxel, cisplatin, and 5‐FU) has a trend of further improving treatment efficacy compared with the traditional doublet regimen. 35 , 36 In a phase II study, concurrent chemoradiotherapy with TPF achieved a clinical CR rate of 52.4%, much higher than the previously reported CR rate of 20%. 9 However, the high ... sap foreign currency valuation document typeWebApr 4, 2024 · First-line Combination Therapy for Recurrent, Unresectable, or Metastatic Disease (With No Surgery or RT Option) 1. Cisplatin or carboplatin + 5-FU + … sap foreign currency valuation tcodeWebGemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial Clinical Pharmacy and Pharmacology JAMA Oncology JAMA Network This open-label, single-arm, phase 2 clinical trial evaluates whether nab-paclitaxel plus gemcitabine-cisplatin prolongs survival vs that for historical populat short support socks for men